Speaker Profile

Ph.D., Vice President of Business Development, Pear Bio

Dr Schlicher leads corporate strategy for business development at Pear Bio. She recently led strategy and launch for Genialis ResponderIDTM (2021). She brings over 20 years of experience in precision medicine, diagnostics, and entrepreneurial leadership. Robyn has patented inventions in regenerative medicine and is a recognized global expert in advanced analytical techniques. Her publication on drug delivery by targeted cavitation has been widely cited and highlighted worldwide. She earned her doctorate in bioengineering from Georgia Institute of Technology and Emory University, receiving National Institutes of Health and Medtronic fellowships. In 2021, Robyn became an inaugural fellow of On Deck Health (ODH1).

Clinical & Research Tools Showcase:
Pear Bio

At Pear Bio, we evaluate cancer drug efficacy using organ-on-a-chip and computer vision to monitor cancer progression of patient-derived tumor samples against potential treatment options. We inform physicians to guide treatment decisions and provide tools to help pharmaceutical companies develop new therapies.

Ex Vivo Imaging AI for Cancer Treatment Guidance
Pear Bio cultures patient tumor samples ex vivo and tests potential treatment options. A proprietary computer vision pipeline finds image-based biomarkers in time-course 3D microscopy data of patient tumor cultures. The platform has applications in guiding treatment decision-making and therapeutics development.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30

The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.